Cargando…
Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial
BACKGROUND: Chronic wounds (e.g. diabetic foot ulcers) reduce the quality of life, yet treatments remain limited. Glucocorticoids (activated by the enzyme 11β-hydroxysteroid dehydrogenase type 1, 11β-HSD1) impair wound healing. OBJECTIVES: Efficacy, safety, and feasibility of 11β-HSD1 inhibition for...
Autores principales: | Ajjan, R A, Hensor, E M A, Del Galdo, F, Shams, K, Abbas, A, Fairclough, R J, Webber, L, Pegg, L, Freeman, A, Taylor, A E, Arlt, W, Morgan, A W, Tahrani, A A, Stewart, P M, Russell, D A, Tiganescu, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942338/ https://www.ncbi.nlm.nih.gov/pubmed/35113805 http://dx.doi.org/10.1530/EJE-21-1197 |
Ejemplares similares
-
11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension
por: Hardy, Rowan S, et al.
Publicado: (2020) -
Effect of AZD4017, a Selective 11β-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal Osteopenia
por: Abbas, Afroze, et al.
Publicado: (2022) -
Automated quantification of 3D wound morphology by machine learning and optical coherence tomography in type 2 diabetes
por: Wang, Yinhai, et al.
Publicado: (2022) -
Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled, phase II study
por: Yadav, Yogesh, et al.
Publicado: (2022) -
Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial
por: Markey, Keira Annie, et al.
Publicado: (2017)